Tang Capital Management LLC Raises Stock Position in Nkarta, Inc. (NASDAQ:NKTX)

Tang Capital Management LLC increased its holdings in shares of Nkarta, Inc. (NASDAQ:NKTX - Free Report) by 252.9% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 2,293,719 shares of the company's stock after acquiring an additional 1,643,719 shares during the period. Tang Capital Management LLC owned about 3.25% of Nkarta worth $5,711,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of the business. ProShare Advisors LLC bought a new stake in shares of Nkarta during the fourth quarter worth $45,000. Nuveen Asset Management LLC increased its stake in Nkarta by 18.3% in the 4th quarter. Nuveen Asset Management LLC now owns 140,113 shares of the company's stock worth $349,000 after buying an additional 21,627 shares during the period. Millennium Management LLC increased its stake in Nkarta by 98.8% in the 4th quarter. Millennium Management LLC now owns 600,142 shares of the company's stock worth $1,494,000 after buying an additional 298,317 shares during the period. Jefferies Financial Group Inc. lifted its holdings in Nkarta by 901.7% during the 4th quarter. Jefferies Financial Group Inc. now owns 2,504,219 shares of the company's stock valued at $6,236,000 after buying an additional 2,254,219 shares in the last quarter. Finally, Forefront Analytics LLC boosted its position in Nkarta by 70.3% in the 4th quarter. Forefront Analytics LLC now owns 30,046 shares of the company's stock valued at $75,000 after buying an additional 12,400 shares during the period. Hedge funds and other institutional investors own 80.54% of the company's stock.

Analysts Set New Price Targets

NKTX has been the topic of a number of research analyst reports. Needham & Company LLC dropped their target price on shares of Nkarta from $11.00 to $10.00 and set a "buy" rating on the stock in a research note on Thursday, May 15th. HC Wainwright reissued a "buy" rating and issued a $18.00 price objective on shares of Nkarta in a research note on Thursday, March 27th. William Blair restated a "market perform" rating on shares of Nkarta in a report on Thursday, May 15th. Finally, Stifel Nicolaus lowered their target price on Nkarta from $15.00 to $14.00 and set a "buy" rating for the company in a report on Thursday, March 27th. One analyst has rated the stock with a hold rating, five have given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus price target of $14.67.

Nkarta Stock Down 5.6%

NKTX stock traded down $0.10 during trading on Wednesday, hitting $1.70. 351,961 shares of the company's stock traded hands, compared to its average volume of 1,066,344. The firm has a market capitalization of $120.63 million, a P/E ratio of -0.90 and a beta of 0.81. Nkarta, Inc. has a 1 year low of $1.31 and a 1 year high of $8.23. The business has a fifty day simple moving average of $1.79 and a two-hundred day simple moving average of $2.18.

Nkarta (NASDAQ:NKTX - Get Free Report) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($0.43) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.44) by $0.01. On average, equities research analysts predict that Nkarta, Inc. will post -1.7 EPS for the current fiscal year.

Nkarta Company Profile

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.